Focus on Anticoagulation Care

Back to articles

Newer oral anticoagulants increase risk of gastrointestinal bleeding

KEY POINT

Studies of the newer oral anticoagulants dabigatran (Pradaxa—Boehringer Ingelheim) and rivaroxaban (Xarelto—Bayer, Ortho–McNeil Janssen) demonstrated an increased risk of gastrointestinal (GI) bleeding as compared to standard care for atrial fibrillation, venous thromboembolism, and acute coronary syndrome, according to a recent analysis.